Bulletin
Investor Alert

Market Pulse Archives

May 25, 2022, 8:19 a.m. EDT

Verrica's stock slides after getting second complete response letter from FDA

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Verrica Pharmaceuticals Inc. (VRCA)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Verrica Pharmaceuticals Inc. /zigman2/quotes/202949334/composite VRCA -6.22% tumbled 54.5% in premarket trading on Wednesday, the day after the company told investors it received a complete response letter from the Food and Drug Administration relating to the application for the company's experimental treatment for molluscum contagiosum, an infection caused by a poxvirus. The letter cited problems with the contract manufacturing organization Sterling Pharmaceuticals Services LLC, which made the bulk solution drug product used in the therapy, VP-102. Verrica previously received a CRL in September 2021 that also related to an issue with Sterling. Verrica's stock is down 39.3% this year, while the broader S&P 500 /zigman2/quotes/210599714/realtime SPX +3.06% has declined 17.3%.

/zigman2/quotes/202949334/composite
US : U.S.: Nasdaq
$ 2.11
-0.14 -6.22%
Volume: 1.66M
June 24, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$58.07 million
Rev. per Employee
$11,342
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
3,911.74
+116.01 +3.06%
Volume: 3.46B
June 24, 2022 5:05p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.